{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:38:23Z","timestamp":1789544303422,"version":"build-2803163510"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Patients with reduced left ventricular ejection fraction after myocardial infarction (MI) remain at increased risk of sudden cardiac death during the early post-MI period, before implantable cardioverter defibrillator eligibility is confirmed. The wearable cardioverter defibrillator (WCD) offers temporary protection during this vulnerable interval within post-MI care. We evaluated the cost-utility of WCD therapy plus guideline-directed medical therapy (GDMT) vs. GDMT alone from the Spanish healthcare system perspective.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A cost-utility analysis used a Markov state-transition model with monthly cycles and a lifetime horizon for a hypothetical cohort of 1,000 post-MI patients with left ventricular ejection fraction 35% or less at discharge. Early mortality inputs were based on the as-treated VEST analysis; longer-term risks and utilities came from published sources. Direct medical costs used Spanish sources (2025 euros). Deterministic and probabilistic sensitivity analyses were conducted, including a scenario analysis using per-protocol effectiveness estimates from the VEST trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>WCD plus GDMT was associated with projected gains of 0.53 life years and 0.43 quality-adjusted life years (QALYS) vs. GDMT alone (12.83 vs. 12.30 life years; 9.59 vs. 9.16 QALYs). Total lifetime costs were \u20ac113,290 vs. \u20ac102,032, giving incremental costs of \u20ac11,259 and an incremental cost-effectiveness ratio of \u20ac26,145 per QALY gained, below the \u20ac30,000 threshold. The probability of cost-effectiveness was 78.3% for patients during the early post-MI period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In Spain, temporary WCD use alongside GDMT after MI shows potential to improve health outcomes at an incremental cost that falls within commonly cited willingness-to-pay thresholds. These findings support adoption of WCD therapy for patients at transiently high risk of sudden cardiac death, while highlighting the importance of appropriate patient selection and adherence in clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1832880","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T04:43:59Z","timestamp":1780029839000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Cost-utility analysis of the wearable cardioverter defibrillator in high-risk post-myocardial infarction patients in the Spanish healthcare system"],"prefix":"10.3389","volume":"13","author":[{"given":"Jos\u00e9","family":"Gonz\u00e1lez Costello","sequence":"first","affiliation":[{"name":"Cardiomyopathies, Advanced Heart Failure and Heart Transplant Unit, Department of Cardiology, Hospital Universitari de Bellvitge, BIOHEART Cardiovascular Diseases Research Group, IDIBELL, L\u2019Hospitalet de Llobregat","place":["Barcelona, Spain"]},{"name":"Department of Clinical Sciences, School of Medicine, Universitat de Barcelona","place":["Barcelona, Spain"]},{"name":"CIBER de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor","family":"Exposito Garcia","sequence":"additional","affiliation":[{"name":"Arrhythmia Service, Cardiology Department, University Hospital Marques de Valdecilla","place":["Santander, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eoin","family":"Moloney","sequence":"additional","affiliation":[{"name":"Optimax Access Ltd., Southampton University Science Park","place":["Southampton, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasileios","family":"Kontogiannis","sequence":"additional","affiliation":[{"name":"Optimax Access Ltd., Southampton University Science Park","place":["Southampton, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Javanbakht","sequence":"additional","affiliation":[{"name":"Optimax Access Ltd., Southampton University Science Park","place":["Southampton, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farai","family":"Goromonzi","sequence":"additional","affiliation":[{"name":"ZOLL Medical Deutschland GmbH","place":["Cologne, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Both","sequence":"additional","affiliation":[{"name":"ZOLL Medical Deutschland GmbH","place":["Cologne, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ra\u00fal","family":"Moreno","sequence":"additional","affiliation":[{"name":"CIBER de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III","place":["Madrid, Spain"]},{"name":"Cardiology Department, University Hospital La Paz","place":["Madrid, Spain"]},{"name":"Instituto de Investigaci\u00f3n Sanitaria Hospital Universitario La Paz (IdiPAZ)","place":["Madrid, Spain"]},{"name":"Universidad Aut\u00f3noma de Madrid","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/S1131-3587(13)70060-8","article-title":"Epidemiolog\u00eda de la muerte s\u00fabita cardiaca","volume":"13","author":"de Asmundis","year":"2013","journal-title":"Rev Esp Cardiol Supl"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e020462","DOI":"10.1136\/bmjgh-2025-020462","article-title":"Epidemiology of sudden cardiac arrest in the western Mediterranean area based on a prospective registry","volume":"10","author":"Azeli","year":"2025","journal-title":"BMJ Glob Health"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1016\/j.jacc.2022.02.041","article-title":"Incidence of sudden cardiac death in the European union","volume":"79","author":"Empana","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S0300-8932(99)74993-6","article-title":"Epidemiolog\u00eda de la muerte s\u00fabita card\u00edaca en Espa\u00f1a","volume":"52","author":"Marrugat","year":"1999","journal-title":"Rev Esp Cardiol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990\u20132019: update from the GBD 2019 study","volume":"76","author":"Roth","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.resuscitation.2016.06.004","article-title":"Eureca ONE-27 nations, ONE Europe, ONE registry","volume":"105","author":"Gr\u00e4sner","year":"2016","journal-title":"Resuscitation"},{"key":"B7","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.resuscitation.2019.12.042","article-title":"Survival after out-of-hospital cardiac arrest in Europe\u2014results of the EuReCa TWO study","volume":"148","author":"Gr\u00e4sner","year":"2020","journal-title":"Resuscitation"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1093\/eurheartj\/ehac262","article-title":"2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death","volume":"43","author":"Zeppenfeld","year":"2022","journal-title":"Eur Heart J"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1056\/NEJM199612263352601","article-title":"Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia","volume":"335","author":"Moss","year":"1996","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1093\/eurheartj\/eht109","article-title":"Risk stratification after myocardial infarction: is left ventricular ejection fraction enough to prevent sudden cardiac death?","volume":"34","author":"Dagres","year":"2013","journal-title":"Eur Heart J"},{"key":"B11","doi-asserted-by":"publisher","first-page":"CJ-21-0999","DOI":"10.1253\/circj.CJ-21-0999","article-title":"Reduced left ventricular ejection fraction is a risk for sudden cardiac death in the early period after hospital discharge in patients with acute myocardial infarction","volume":"86","author":"Hanada","year":"2022","journal-title":"Circ J"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3437","DOI":"10.1093\/eurheartj\/ehaa226","article-title":"Clinical effectiveness of primary prevention implantable cardioverter-defibrillators: results of the EU-CERT-ICD controlled multicentre cohort study","volume":"41","author":"Zabel","year":"2020","journal-title":"Eur Heart J"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1056\/NEJMoa043938","article-title":"Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both","volume":"352","author":"Solomon","year":"2005","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1161\/CIRCULATIONAHA.113.007497","article-title":"Sudden cardiac death early after myocardial infarction","volume":"129","author":"Zaman","year":"2014","journal-title":"Circulation"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1001\/jama.2008.553","article-title":"Sudden death after myocardial infarction","volume":"300","author":"Adabag","year":"2008","journal-title":"JAMA"},{"key":"B16","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jacc.2010.04.016","article-title":"Aggregate national experience with the wearable cardioverter-defibrillator","volume":"56","author":"Chung","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.jacep.2018.11.011","article-title":"Wearable cardioverter-defibrillator therapy for the prevention of sudden cardiac death","volume":"5","author":"Masri","year":"2019","journal-title":"JACC Clin Electrophysiol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1056\/NEJMoa1800781","article-title":"Wearable cardioverter\u2013defibrillator after myocardial infarction","volume":"379","author":"Olgin","year":"2018","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1111\/jce.14404","article-title":"Impact of wearable cardioverter-defibrillator compliance on outcomes in the VEST trial: as-treated and per-protocol analyses","volume":"31","author":"Olgin","year":"2020","journal-title":"J Cardiovasc Electrophysiol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1161\/CIRCULATIONAHA.115.019124","article-title":"Experience with the wearable cardioverter-defibrillator in patients at high risk for sudden cardiac death","volume":"134","author":"W\u00e4\u00dfnig","year":"2016","journal-title":"Circulation"},{"key":"B21","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s00392-020-01657-2","article-title":"Protected risk stratification with the wearable cardioverter-defibrillator: results from the WEARIT-II-EUROPE registry","volume":"110","author":"Veltmann","year":"2021","journal-title":"Clin Res Cardiol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1093\/europace\/euaa268","article-title":"Wearable cardioverter-defibrillator in patients with a transient risk of sudden cardiac death: the WEARIT-France cohort study","volume":"23","author":"Garcia","year":"2021","journal-title":"EP Europace"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1161\/CIRCULATIONAHA.115.015677","article-title":"Use of the wearable cardioverter defibrillator in high-risk cardiac patients","volume":"132","author":"Kutyifa","year":"2015","journal-title":"Circulation"},{"key":"B24","article-title":"Utilidad del chaleco desfibrilador en m\u00faltiples indicaciones cl\u00ednicas (utility of the wearable cardioverter-defibrillator across multiple clinical indications)","volume-title":"REC Cardioclinics","author":"Lara-Garcia","year":""},{"key":"B25","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ijcard.2022.04.003","article-title":"The value of wearable cardioverter defibrillator in adult patients with recent myocardial infarction: economic and clinical implications from a health technology assessment perspective","volume":"356","author":"Botto","year":"2022","journal-title":"Int J Cardiol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s41669-024-00553-z","article-title":"Cost-Utility analysis of LifeVest\u00ae in post-myocardial infarction patients at risk of sudden cardiac death in England","volume":"9","author":"Kontogiannis","year":"2025","journal-title":"Pharmacoecon Open"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.33963\/v.phj.108491","article-title":"Cost-utility analysis of the use of a wearable cardioverter defibrillator (LifeVest\u00ae) versus standard of care in the prevention of sudden cardiac death in patients after myocardial infarction","volume":"83","author":"Mitkowski","year":"2025","journal-title":"Polish Heart Journal"},{"key":"B28","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/j.1524-4733.2008.00489.x","article-title":"Transferability of economic evaluations across jurisdictions: ISPOR good research practices task force report","volume":"12","author":"Drummond","year":"2009","journal-title":"Value Health"},{"key":"B29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","article-title":"Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"key":"B30","doi-asserted-by":"publisher","first-page":"102448","DOI":"10.1016\/j.gaceta.2025.102448","article-title":"Guideline for the economic evaluation of medicines: a proposal by the Spanish national health system\u2019s advisory committee for pharmaceutical financing","volume":"39","author":"Trapero-Bertran","year":"2025","journal-title":"Gac Sanit"},{"key":"B31","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s10198-010-0244-4","article-title":"Spanish Recommendations on economic evaluation of health technologies","volume":"11","author":"L\u00f3pez-Bastida","year":"2010","journal-title":"Eur J Health Econ"},{"key":"B32","doi-asserted-by":"publisher","first-page":"3601","DOI":"10.21873\/invivo.12205","article-title":"Comparison of the outcome of patients protected by the wearable cardioverter defibrillator (WCD) for <90 wear days versus \u226590 wear days","volume":"34","author":"Dreher","year":"2020","journal-title":"In Vivo (Brooklyn)"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/j.jacc.2003.11.038","article-title":"Analysis of mortality events in the multicenter automatic defibrillator implantation trial (MADIT-II)","volume":"43","author":"Greenberg","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.jacc.2011.06.007","article-title":"Implantation-Related complications of implantable cardioverter-defibrillators and cardiac resynchronization therapy devices","volume":"58","author":"van Rees","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1016\/j.jacc.2010.06.037","article-title":"Acute lead dislodgements and in-hospital mortality in patients enrolled in the national cardiovascular data registry implantable cardioverter defibrillator registry","volume":"56","author":"Cheng","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1093\/europace\/eup362","article-title":"Contemporary management of and outcomes from cardiac device related infections","volume":"12","author":"Margey","year":"2010","journal-title":"Europace"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/j.jacc.2007.01.072","article-title":"Management and outcome of permanent pacemaker and implantable cardioverter-defibrillator infections","volume":"49","author":"Sohail","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.cardfail.2004.02.003","article-title":"Hospitalized heart failure: rates and long-term mortality","volume":"10","author":"Shahar","year":"2004","journal-title":"J Card Fail"},{"key":"B39","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.ijcard.2018.07.137","article-title":"Relationship between left ventricular ejection fraction and mortality after myocardial infarction complicated by heart failure or left ventricular dysfunction","volume":"272","author":"Hall","year":"2018","journal-title":"Int J Cardiol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"4597","DOI":"10.1093\/eurheartj\/ehaf668","article-title":"Sudden cardiac death in newly diagnosed non-ischaemic or ischaemic cardiomyopathy assessed with a wearable cardioverter-defibrillator: the German nationwide SCD-PROTECT study","volume":"46","author":"Duncker","year":"2025","journal-title":"Eur Heart J"},{"key":"B41","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.114.009924","article-title":"Evolution of left ventricular ejection fraction after acute myocardial infarction","volume":"130","author":"Sj\u00f6blom","year":"2014","journal-title":"Circulation"},{"key":"B42","year":"2024"},{"key":"B43","year":"2014"},{"key":"B44","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"B45","article-title":"Uso del chaleco desfibrilador en Espa\u00f1a: experiencia con los 200 primeros pacientes [Abstract]","volume":"78","author":"Escobar","year":"2025","journal-title":"Rev Esp Cardiol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"e002787","DOI":"10.1136\/openhrt-2024-002787","article-title":"Appropriate use of wearable defibrillators with multiparametric evaluation to avoid unnecessary defibrillator implantation","volume":"11","author":"Matteucci","year":"2024","journal-title":"Open Heart"},{"key":"B47","first-page":"1","article-title":"Spain: health system review","volume":"20","author":"Bernal-Delgado","year":"2018","journal-title":"Health Syst Transit"},{"key":"B48","year":"2024"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e003648","DOI":"10.1136\/openhrt-2025-003648","article-title":"Wearable cardioverter defibrillator for transient arrhythmic risk and sudden cardiac death prevention: a systematic review and updated meta-analysis","volume":"12","author":"Matteucci","year":"2025","journal-title":"Open Heart"},{"key":"B50","doi-asserted-by":"publisher","first-page":"w20343","DOI":"10.4414\/smw.2020.20343","article-title":"Use of the wearable cardioverter-defibrillator\u2014the Swiss experience","volume":"150","author":"Kovacs","year":"2020","journal-title":"Swiss Med Wkly"},{"key":"B51","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1177\/1474515118790365","article-title":"Indications for and outcome in patients with the wearable cardioverter-defibrillator in a nurse-based training programme: results of the Austrian WCD registry","volume":"18","author":"Odeneg","year":"2019","journal-title":"Eur J Cardiovasc Nurs"},{"key":"B52","doi-asserted-by":"publisher","first-page":"433","DOI":"10.2147\/PPA.S400086","article-title":"Evaluation of a standardized training and adherence surveillance programme to overcome quality-of-life impairments and enhance compliance in patients treated with wearable cardioverter defibrillator","volume":"17","author":"Kellnar","year":"2023","journal-title":"Patient Prefer Adherence"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1832880\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T04:44:07Z","timestamp":1780029847000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1832880\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":52,"alternative-id":["10.3389\/fcvm.2026.1832880"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1832880","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"article-number":"1832880"}}